BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer DGAT1 inhibition could treat glioblastoma multiforme (GBM) by promoting fat catabolism. Levels of triglycerides and lipid droplets were higher in postmortem brain tissue from GBM patients than individuals without...
BioCentury | Feb 20, 2019
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting DGAT1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, levels of DGAT1 were higher in CD4 + T cells from the...
BioCentury | Sep 19, 2017
Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
BioCentury | Sep 8, 2017
Company News

Presage grants MEI rights to cancer candidate voruciclib

Presage Biosciences (Seattle, Wash.) granted MEI Pharma Inc. (NASDAQ:MEIP) exclusive, worldwide rights to develop and commercialize cancer candidate voruciclib (formerly P1446A) for near-term payments of $2.9 million and up to $181 million in milestones, plus...
BioCentury | Feb 2, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes In vitro , cell culture and mouse studies identified a pyrrolidine-based FFAR1 agonist that could help treat Type II diabetes. Chemical synthesis and testing in cell-based assays of pyrrolidine analogs identified a compound that...
BioCentury | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Transforming growth factor β 1 (TGFB1)

Cancer INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting TGFB1 could help treat metastatic breast cancer. In a human breast cancer cell line, a TGFB1 inhibitor tool compound decreased proliferation, invasion and markers...
BioCentury | May 12, 2016
Translation in Brief

PET projects

Recent high-profile failures in clinical trials for Alzheimer's disease (AD) have underscored the role that imaging agents could play in identifying the right trial populations and tracking their responses. AC Immune S.A. and Biogen Inc....
BioCentury | Apr 9, 2015
Distillery Techniques

Techniques: PET β-amyloid score as a predictor of the degree of amyloid pathology in Alzheimer's disease (AD)

Biomarkers TECHNOLOGY: Tissue markers PET-based measurement of β-amyloid plaque severity in the brain could help stratify AD patients for clinical trials. In 35 patients with a confirmed diagnosis of AD, the severity of β-amyloid plaque...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
BioCentury | Sep 22, 2014
Company News

Piramal Enterprises supply/service news

Piramal said it is discontinuing its early stage drug discovery research and focusing on its late-stage clinical development. The company said 200 researchers at its facility in Goregaon have been given a voluntary early separation...
Items per page:
1 - 10 of 69
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer DGAT1 inhibition could treat glioblastoma multiforme (GBM) by promoting fat catabolism. Levels of triglycerides and lipid droplets were higher in postmortem brain tissue from GBM patients than individuals without...
BioCentury | Feb 20, 2019
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting DGAT1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, levels of DGAT1 were higher in CD4 + T cells from the...
BioCentury | Sep 19, 2017
Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
BioCentury | Sep 8, 2017
Company News

Presage grants MEI rights to cancer candidate voruciclib

Presage Biosciences (Seattle, Wash.) granted MEI Pharma Inc. (NASDAQ:MEIP) exclusive, worldwide rights to develop and commercialize cancer candidate voruciclib (formerly P1446A) for near-term payments of $2.9 million and up to $181 million in milestones, plus...
BioCentury | Feb 2, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes In vitro , cell culture and mouse studies identified a pyrrolidine-based FFAR1 agonist that could help treat Type II diabetes. Chemical synthesis and testing in cell-based assays of pyrrolidine analogs identified a compound that...
BioCentury | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Transforming growth factor β 1 (TGFB1)

Cancer INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting TGFB1 could help treat metastatic breast cancer. In a human breast cancer cell line, a TGFB1 inhibitor tool compound decreased proliferation, invasion and markers...
BioCentury | May 12, 2016
Translation in Brief

PET projects

Recent high-profile failures in clinical trials for Alzheimer's disease (AD) have underscored the role that imaging agents could play in identifying the right trial populations and tracking their responses. AC Immune S.A. and Biogen Inc....
BioCentury | Apr 9, 2015
Distillery Techniques

Techniques: PET β-amyloid score as a predictor of the degree of amyloid pathology in Alzheimer's disease (AD)

Biomarkers TECHNOLOGY: Tissue markers PET-based measurement of β-amyloid plaque severity in the brain could help stratify AD patients for clinical trials. In 35 patients with a confirmed diagnosis of AD, the severity of β-amyloid plaque...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
BioCentury | Sep 22, 2014
Company News

Piramal Enterprises supply/service news

Piramal said it is discontinuing its early stage drug discovery research and focusing on its late-stage clinical development. The company said 200 researchers at its facility in Goregaon have been given a voluntary early separation...
Items per page:
1 - 10 of 69